Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement

References

• Global Burden of Disease Liver Cancer Collaboration: Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the Global, regional, and national level: Results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–1691.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–838.
   PubMed Web of Science ®Google Scholar
• Prorok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol. 1992;14:117–128.
   PubMedGoogle Scholar
• Heleno B, Thomsen MF, Rodrigues DS, et al. Quantification of harms in cancer screening trials: literature review. BMJ. 2013 Sep 16;347:f5334. doi:https://doi.org/10.1136/bmj.f5334
   PubMed Web of Science ®Google Scholar
• Walter SD, Stitt LW. Evaluating the survival of cancer cases detected by screening. Stat Med. 1987;6:885–900.
   PubMed Web of Science ®Google Scholar
• Duffy SW, Nagtegaal ID, Wallis M, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168:98–104.
   PubMed Web of Science ®Google Scholar
• Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328:1237–1243.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Cucchetti A, Erroi V, et al. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol. 2013;19:8808–8821.
   PubMed Web of Science ®Google Scholar
• Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076–1084.
   PubMed Web of Science ®Google Scholar
• Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng A-L, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370.
   PubMed Web of Science ®Google Scholar
• Furlan A, Marin D, Agnello F, et al. Hepatocellular carcinoma presenting at contrast-enhanced multi-detector-row computed tomography or gadolinium-enhanced magnetic resonance imaging as a small (≤2 cm), indeterminate nodule: growth rate and optimal interval time for imaging follow-up. J Comput Assist Tomogr. 2012;36:20–25.
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Trevisani F, Pecorelli A, et al. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol. 2014;61:333–341.
   PubMed Web of Science ®Google Scholar
• Kubota K, Ina H, Okada Y, et al. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci. 2003;48:581–586.
   PubMed Web of Science ®Google Scholar
• Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734–744.
   PubMed Web of Science ®Google Scholar
• Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–297.
   PubMed Web of Science ®Google Scholar
• Trinchet J-C, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987–1997.
   PubMed Web of Science ®Google Scholar
• Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017;65:1196–1205.
   PubMed Web of Science ®Google Scholar
• Cadier B, Bulsei J, Nahon P, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatology. 2017;65:1237–1248.
   PubMed Web of Science ®Google Scholar
• Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624.
   PubMed Web of Science ®Google Scholar
• Moon AM, Weiss NS, Beste LA, et al. No association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis. Gastroenterology. 2018;155:1128–1139.e6.
   PubMed Web of Science ®Google Scholar
• Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol. 1997;123:357–360.
   PubMed Web of Science ®Google Scholar
• Zhang B-H, Yang B-H, Tang Z-Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.
   PubMed Web of Science ®Google Scholar
• Kansagara D, Papak J, Pasha AS, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014;161:261–269.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–733.
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–726.
   PubMed Web of Science ®Google Scholar
• Serti E, Chepa-Lotrea X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis c virus infection normalizes natural killer cell function. Gastroenterology. 2015;149:190–200.e2.
   PubMed Web of Science ®Google Scholar
• Spaan M, van Oord G, Kreefft K, et al. Immunological analysis during interferon-free therapy for chronic hepatitis c virus infection reveals modulation of the natural killer cell compartment. J Infect Dis. 2016;213:216–223.
   PubMed Web of Science ®Google Scholar
• Debes JD, van Tilborg M, Groothuismink ZMA, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology. 2018;154:515–517.e3.
   PubMed Web of Science ®Google Scholar
• Faillaci F, Marzi L, Critelli R, et al. liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis c virus direct-acting antivirals. Hepatology. 2018;68:1010–1024.
   PubMed Web of Science ®Google Scholar
• ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: [email protected]. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734–740. https://pubmed.ncbi.nlm.nih.gov/27288051/
   PubMed Web of Science ®Google Scholar
• Cheung MCM, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741–747.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018;155:411–421.
   PubMed Web of Science ®Google Scholar
• Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol. 2018;69:345–352.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Craxì A. Hepatocellular carcinoma and direct-acting antivirals: a never ending story? Liver Int Off J Int Assoc Study Liver. 2017;37:812–814.
   PubMed Web of Science ®Google Scholar
• Janjua NZ, Wong S, Darvishian M, et al. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. J Viral Hepat. 2020;27:781–793.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Asch SM, et al. Long-Term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71:44–55.
   PubMed Web of Science ®Google Scholar
• Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Kanwal F, Richardson P, et al. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology. 2016;64:130–137.
   PubMed Web of Science ®Google Scholar
• Nahon P, Layese R, Bourcier V, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for hcv in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155(5):1436–1450.e6.
   PubMed Web of Science ®Google Scholar
• Kanda T, Lau GKK, Wei L, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int. 2019;13:649–661.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Kramer J, Duan Z, et al. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014;109:1427–1435.
   PubMed Web of Science ®Google Scholar
• Winters AC, Sung JC, Wyatt B, et al. At diagnosis of hepatocellular carcinoma, African Americans with hepatitis C have better liver function than other patients. Clin Liver Dis. 2018;12:109–112.
   Google Scholar
• Shaltiel T, Zheng S, Siderides C, et al. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer. 2021;127:1395–1406.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444–1453.
   PubMed Web of Science ®Google Scholar
• Kim SU, Seo YS, Lee HA, et al. Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis b: a multicenter study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2020;29:832–837.
   Google Scholar
• Li W, Deng R, Liu S, et al. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: the emerging role of non-viral risk factors. Liver Int. 2020;40:2316–2325.
   PubMed Web of Science ®Google Scholar
• Chan HL-Y, Tse C-H, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:177–182.
   PubMed Web of Science ®Google Scholar
• Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142. DOI:https://doi.org/10.1053/j.gastro.2012.02.007.
   Google Scholar
• Kawanaka M, Nishino K, Nakamura J, et al. Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving Long-Term Nucleos(t)ide analogue therapy. Liver Cancer. 2014;3:41–52.
   PubMed Web of Science ®Google Scholar
• Wang LH-C, Huang W, Lai M-D, et al. Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis. 2012;33:466–472.
   PubMed Web of Science ®Google Scholar
• Sung W-K, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44:765–769.
   PubMed Web of Science ®Google Scholar
• Yaginuma K, Kobayashi H, Kobayashi M, et al. Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J Virol. 1987;61:1808.
   PubMed Web of Science ®Google Scholar
• Jin Y, Wu D, Yang W, et al. Hepatitis B virus x protein induces epithelial-mesenchymal transition of hepatocellular carcinoma cells by regulating long non-coding RNA. Virol J. 2017;14:1–9.
   PubMed Web of Science ®Google Scholar
• Cheng S-T, Ren J-H, Cai X-F, et al. HBx-elevated SIRT2 promotes HBV replication and hepatocarcinogenesis. Biochem Biophys Res Commun. 2018;496:904–910.
   PubMed Web of Science ®Google Scholar
• Hsieh A, Kim H-S, Lim S-O, et al. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling. Cancer Lett. 2011;300:162–172.
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis B Core–Related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019;157:1518–1529.e3.
   PubMed Web of Science ®Google Scholar
• Muhimpundu S, Conway RBN, Warren Andersen S, et al. Racial differences in hepatocellular carcinoma incidence and risk factors among a low socioeconomic population. Cancers (Basel). 2021;13:3710.
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896–904.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723–1730.
   PubMed Web of Science ®Google Scholar
• Leoni S, Tovoli F, Napoli L, et al. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J. Gastroenterol. Baishideng Publishing Group Co 2018 3361–3373 https://doi.org/10.3748/wjg.v24.i30.3361
   Google Scholar
• Aby E, Phan J, Truong E, et al. Inadequate hepatocellular carcinoma screening in patients with nonalcoholic steatohepatitis cirrhosis. J Clin Gastroenterol. 2019;53:142–146.
   PubMed Web of Science ®Google Scholar
• Foerster F, Gairing SJ, Müller L, et al. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options. J Hepatol. 2022;76:446–457.
   PubMed Web of Science ®Google Scholar
• Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48:696–703.
   Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155:1828–1837.e2.
   PubMed Web of Science ®Google Scholar
• Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: a patient guideline. J Hepatol. 2021;10:100322.
   Google Scholar
• Loomba R, Lim JK, Patton H, et al. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology. 2020;158:1822–1830.
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154:1706–1718.e1.
   PubMed Web of Science ®Google Scholar
• Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45:169–177.
   PubMed Web of Science ®Google Scholar
• Del Poggio P, Olmi S, Ciccarese F, et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12:1927–1933.e2.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu Y, Li Y, et al. Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016. Oncotarget. 2017;8:75418–75426.
   PubMedGoogle Scholar
• Chehabeddine L, Al Saleh T, Baalbaki M, et al. Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents. Crit Rev Toxicol. 2019;49:262–279.
   PubMed Web of Science ®Google Scholar
• Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular Carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181–223.
   PubMed Web of Science ®Google Scholar
• Kim SY, An J, Lim Y-S, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3:456–463.
   PubMed Web of Science ®Google Scholar
• Chan MV, McDonald SJ, Ong -Y-Y, et al. HCC screening: assessment of an abbreviated non-contrast MRI protocol. Eur Radiol Exp. 2019;3:49.
   PubMedGoogle Scholar
• Nicholson BD, Jones NR, Protheroe A, et al. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: a diagnostic test accuracy systematic review. Cancer Epidemiol. 2019;59:15–21.
   PubMed Web of Science ®Google Scholar
• Schieving JH, De Vries M, Van Vugt JMG, et al. Alpha-fetoprotein, a fascinating protein and biomarker in neurology. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2014;18:243–248.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434–441.
   PubMed Web of Science ®Google Scholar
• Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen. 1999;6:108–110.
   PubMed Web of Science ®Google Scholar
• Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta Int J Clin Chem. 2013;425:212–220.
   PubMed Web of Science ®Google Scholar
• Choi J, Kim GA, Han S, et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology. 2019;69:1983–1994.
   PubMed Web of Science ®Google Scholar
• Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008;2:17–30.
   PubMed Web of Science ®Google Scholar
• Poté N, Cauchy F, Albuquerque M, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848–854.
   PubMed Web of Science ®Google Scholar
• Koike Y, Shiratori Y, Sato S , et al. Des-Carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma a prospective analysis of 227 patients. Cancer. 2001 Feb 1;91(3):561–9.
   Google Scholar
• Loglio A, Iavarone M, Facchetti F, et al. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. Liver Int Off J Int Assoc Study Liver. 2020;40:1987–1996.
   PubMed Web of Science ®Google Scholar
• Tarao K, Nozaki A, Komatsu H, et al. Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases. World J Hepatol. 2020;12:1046–1054.
   PubMed Web of Science ®Google Scholar
• Caviglia GP, Ribaldone DG, Abate ML, et al. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scand J Gastroenterol. 2018;53:734–740.
   PubMed Web of Science ®Google Scholar
• Ricco G, Cosma C, Bedogni G, et al. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark Sect Dis Markers. 2020;29:189–196.
   PubMed Web of Science ®Google Scholar
• T-h S, Peng C-Y, Chang S-H, et al. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc Taiwan Yi Zhi. 2022;121:703–711.
   PubMed Web of Science ®Google Scholar
• Degasperi E, Perbellini R, D’Ambrosio R, et al. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther. 2022;55:350–359.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2014;23:144–153.
   Google Scholar
• Best J, Bechmann LP, Sowa J-P, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. 2020 Mar;18(3):728–735. https://doi.org/10.1016/j.cgh.2019.11.012
   Google Scholar
• Liu M, Wu R, Liu X, et al. Validation of the GALAD model and establishment of GAAP model for diagnosis of hepatocellular Carcinoma in Chinese patients. J Hepatocell Carcinoma. 2020;7:219.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–1289.
   PubMed Web of Science ®Google Scholar
• WHO classification of tumours of the digestive system. [Internet]. cited 2021 Dec 8]. Available from 2021 Dec 8: https://www.cabdirect.org/cabdirect/abstract/20113051318.
   Google Scholar
• Tovoli F, Guerra P, Iavarone M, et al. Surveillance for hepatocellular Carcinoma also improves survival of incidentally detected intrahepatic cholangiocarcinoma arisen in liver cirrhosis. Liver Cancer. 2020;9:744–755.
   PubMed Web of Science ®Google Scholar
• Elsayes KM, Hooker JC, Agrons MM, et al. Version of LI-RADS for CT and MR imaging: An update. Radiogr Rev Publ Radiol Soc N Am Inc. 2017;37:1994–2017.
   Google Scholar
• Kono Y, Lyshchik A, Cosgrove D, et al. Contrast Enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS®): the official version by the American college of radiology (ACR). Ultraschall Med Stuttg Ger. 2017 1980;38:85–86.
   PubMed Web of Science ®Google Scholar
• Del Poggio P, Mazzoleni M, Lazzaroni S, et al. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol. 2021;27:6180–6190.
   PubMed Web of Science ®Google Scholar
• Shah S, Bellows BA, Adedipe AA, et al. Perceived barriers in the use of ultrasound in developing countries. Crit Ultrasound J. 2015;7:28.
   PubMedGoogle Scholar
• Jepsen P, West J. We need stronger evidence for (or against) hepatocellular carcinoma surveillance. J Hepatol. 2021;74:1234–1239.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Singal AG. Surveillance for hepatocellular Carcinoma: Current best practice and future direction. Gastroenterology. 2019;157:54–64.
   PubMed Web of Science ®Google Scholar
• Poustchi H, Farrell GC, Strasser SI, et al. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology. 2011;54:1998–2004.
   PubMed Web of Science ®Google Scholar
• Ganne-Carrié N, Piscaglia F. Non-enhanced MRI surveillance for HCC: a new tool for all, none or selected patients at risk? J Hepatol. 2020;72:607–609.
   PubMed Web of Science ®Google Scholar
• International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983–993.
   PubMed Web of Science ®Google Scholar